Maya Health's Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
Similar Posts
Medical Applications of Ketamine & Common Misconceptions with Christi Myers, Flow Integrative
In this episode, Christi provides insight into how ketamine impacts people’s physical and mental health. She goes into the comparison of ketamine’s effects compared to other psychedelics and how Flow Integrative’s patient care is unique.
Psilocybin as an Agent for Human and Cultural Development with Jahan Khamsehzadeh Ph.D.
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.
Psychedelic Business Roundup- Is California Next For Legalizing Psychedelics?
April 26, 2021- This week’s Psychedelic Business News Round Up’s…
Examining Ketamine Therapy with Myriam Barthes, Journey Clinical
In today’s episode, Myriam describes the impact of ketamine on the mind and the body, and specifically how ketamine therapy compares to other psychedelic-assisted therapies.
The Spotlight Roundup-Is California Next For Legalizing Psychedelics?
June 22, 2021- This week’s Psychedelic Business News top stories…
Mixing Psychedelics & Antidepressants: Is it Safe? | NEW Psilocybin Study
As using psychedelics as medicines for mental health conditions has become more popular, it has been an open question of whether substances such as psilocybin (magic mushrooms) can safely be combined with anti-depressants such as SSRIs.
Now, Compass Pathways (CMPS) has released a small study, which showed that it is in fact safe to combine the two drugs. This is the second such small study to come to this conclusion. Earlier this year, MindMed, (MNMD / MMED) had released data on a similar study, with similar results
However, it is important to note that these are two very small studies, and that nothing has been definitively proven yet.
Many argue that psychedelics like psilocybin should be a replacement for depression medications such as SSRIs, not another layer of medicine. While I am sympathetic to this view, we must ultimately follow the science.
Compass Pathways will use the results of this trial to inform the design of their upcoming phase 3 trial testing whether psilocybin can treat treatment resistant depression.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
#psychedelics #antidepressants #psilocybin